Thermo Fisher Scientific TMO Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.28B-21.4% | $9.88B+145% | $2.01B-56.9% | $4.6B-35.1% | $4.17B-24.4% | ||
| $4M-75.0% | $5M-50.0% | $7M-36.4% | $3M-72.7% | $16M+129% | ||
| $1.68B+23.3% | $1.67B+16.1% | $1.62B+5.1% | $1.44B-3.1% | $1.37B-3.9% | ||
| —— | —— | —— | —— | —— | ||
| $1.93B+3.4% | $1.88B+4.1% | $1.98B+1.3% | $1.95B-1.4% | $1.86B-8.6% | ||
| $942M+7.8% | $889M+17.7% | $990M+9.8% | $947M+14.8% | $874M+11.1% | ||
| $22.32B-4.5% | $28.71B+29.7% | $22.3B-6.3% | $24.58B-3.5% | $23.38B-1.1% | ||
| $10.66B+14.2% | $10.57B+13.5% | $10.18B+8.1% | $9.64B+3.8% | $9.33B+0.1% | ||
| $55.19B+18.7% | $49.36B+7.7% | $49.29B+5.5% | $47.25B+7.8% | $46.49B+6.0% | ||
| -$258M-125% | $1.49B+17.7% | $842M-25.0% | $624M-58.8% | $1.04B-42.5% | ||
| $113.28B+14.4% | $110.34B+13.4% | $103.02B+2.6% | $101.23B+2.8% | $99.04B+2.0% | ||
| $2.93B+2.2% | $2.71B-5.0% | $2.85B+7.1% | $2.81B+8.3% | $2.87B+8.9% | ||
| —— | —— | —— | —— | —— | ||
| $14.62B+11.0% | $15.19B+13.9% | $14.89B+2.0% | $12.72B-13.9% | $13.17B-5.5% | ||
| $42.95B+26.4% | $39.17B+26.1% | $35.48B+1.1% | $35.03B-0.5% | $33.99B-4.0% | ||
| $213M+6.5% | $213M+5.4% | $196M-2.0% | $196M-5.3% | $200M-7.0% | ||
| $213M+6.5% | $213M+5.4% | $196M-2.0% | $196M-5.3% | $200M-7.0% | ||
| $4.42B+11.3% | $4.27B+7.1% | $4.28B-1.5% | $4.27B-2.8% | $3.97B-13.1% | ||
| —— | —— | —— | —— | —— | ||
| $60.63B+11.4% | $59.16B+11.4% | $57.35B+11.5% | $55.9B+11.9% | $54.45B+12.2% | ||
| -$2.5B-6.6% | -$2.45B+9.2% | -$2.8B-13.1% | -$2.8B-15.9% | -$2.34B+15.2% | ||
| $25.36B+19.2% | $22.31B+16.0% | $22.31B+22.4% | $21.27B+16.9% | $21.27B+17.0% | ||
| $51.93B+5.2% | $53.41B+7.7% | $51.02B+4.1% | $50.51B+6.5% | $49.39B+8.5% | ||
| $113.28B+14.4% | $110.34B+13.4% | $103.02B+2.6% | $101.23B+2.8% | $99.04B+2.0% | ||
| $149M-9.7% | $147M-15.0% | $155M-24.0% | $160M-20.8% | $165M-16.2% | ||
| $2.63B+5.7% | $2.66B+9.9% | $2.77B+7.8% | $2.67B+11.1% | $2.49B+7.8% | ||
| $2.68B+12.1% | $2.61B+33.0% | $2.47B+29.4% | $2.6B+28.3% | $2.39B+25.4% | ||
| —— | —— | —— | —— | —— | ||
| $1M-75.0% | $1M-83.3% | $1M-87.5% | $1M-85.7% | $4M-55.6% | ||
| $5.97B+32.3% | $5.87B+30.7% | $5.02B+20.1% | $4.62B+5.4% | $4.52B+6.5% | ||
| $19.15B+24.9% | $15.84B+2.0% | $16.24B-0.1% | $15.15B-2.4% | $15.32B-4.5% | ||
| $5.97B+32.3% | $5.87B+30.7% | $5.02B+20.1% | $4.62B+5.4% | $4.52B+6.5% | ||
| $2M-99.9% | $253M-83.8% | $1.56B-21.8% | $1.81B— | $1.81B— | ||
| $5.97B+32.3% | $5.87B+30.7% | $5.02B+20.1% | $4.62B+5.4% | $4.52B+6.5% | ||
| $1.57B+10.3% | $2B+0.4% | $1.88B+3.3% | $1.52B+1.5% | $1.42B+8.0% | ||
| $1.03B-8.3% | $1.18B+4.0% | $1.16B-18.8% | $1.12B-22.9% | $1.13B-21.0% | ||
| $1.57B+10.3% | $2B+0.4% | $1.88B+3.3% | $1.52B+1.5% | $1.42B+8.0% | ||
| $3.69B+22.2% | $3.33B+4.1% | $3.21B-5.4% | $3.2B+6.0% | $3.02B+1.2% | ||
| —— | —— | —— | —— | —— | ||
| $1.03B-8.3% | $1.18B+4.0% | $1.16B-18.8% | $1.12B-22.9% | $1.13B-21.0% | ||
| $40.07B+27.7% | $35.85B+23.4% | $31.86B+2.1% | $33.02B+9.0% | $31.37B+0.7% | ||
| $1.03B-8.3% | $1.18B+4.0% | $1.16B-18.8% | $1.12B-22.9% | $1.13B-21.0% | ||
| $43.27B+26.3% | $39.46B+25.9% | $35.75B+1.0% | $35.3B-0.5% | $34.26B-4.0% | ||
| $18.71B+3.3% | $18.56B+3.3% | $18.33B+2.8% | $18.23B+3.3% | $18.11B+3.6% | ||
| $445M+0.2% | $445M+0.2% | $445M+0.2% | $444M+0.2% | $444M+0.2% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| —— | —— | —— | —— | —— | ||
| $149M-9.7% | $147M-15.0% | $155M-24.0% | $160M-20.8% | $165M-16.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $1.000.0% | $1.000.0% | $1.000.0% | $1.000.0% | $1.000.0% | ||
| 1.2B0.0% | 1.2B0.0% | 1.2B0.0% | 1.2B0.0% | 1.2B0.0% | ||
| 445.5M+0.3% | 445.2M+0.3% | 444.6M+0.2% | 444.4M+0.3% | 444.2M+0.3% | ||
| $3.09B+9.6% | $3.53B+59.6% | $3.82B-7.1% | $2.21B-56.8% | $2.82B-36.7% | ||
| $43.27B+26.3% | $39.46B+25.9% | $35.75B+1.0% | $35.3B-0.5% | $34.26B-4.0% | ||
| $39.75B+27.4% | $36.61B+28.3% | $33.08B+0.1% | $32.4B+1.1% | $31.19B-4.5% | ||
| $91M-5.2% | $94M-1.1% | $95M-8.7% | $98M-5.8% | $96M-11.1% | ||
| —— | —— | —— | —— | —— | ||
| $2.11B+102% | $1.49B+17.7% | $842M-25.0% | $624M-58.8% | $1.04B-42.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $40.07B+27.7% | $35.85B+23.4% | $31.86B+2.1% | $33.02B+9.0% | $31.37B+0.7% | ||
| $7M+121% | $7M+121% | $7M+135% | -$35M-192% | -$33M-175% | ||
| —— | —— | —— | —— | —— | ||
| $100.000.0% | $100.000.0% | $100.000.0% | $100.000.0% | $100.000.0% | ||
| 50K0.0% | 50K0.0% | 50K0.0% | 50K0.0% | 50K0.0% | ||
| 0— | 0— | 0— | 0— | 0— | ||
| $121M-5.5% | $122M+1.7% | $129M+1.6% | $126M+9.6% | $128M+7.6% | ||
| $65M+10.2% | $70M+40.0% | $85M+60.4% | $74M+51.0% | $59M+15.7% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| 73.9M+10.6% | 68.9M+9.3% | 68.9M+12.7% | 66.8M+9.2% | 66.8M+9.2% | ||
| $420M-20.0% | $419M-20.2% | $515M-1.7% | $520M-25.9% | $525M-24.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Thermo Fisher Scientific's total assets?
- Thermo Fisher Scientific (TMO) holds $113.28B in total assets, up 14.4% year over year.
- How much debt does Thermo Fisher Scientific have?
- Thermo Fisher Scientific carries $43.2B in total debt against $51.9B of shareholders' equity, a debt-to-equity ratio of 0.83.
- How much cash does Thermo Fisher Scientific have?
- Thermo Fisher Scientific holds $3.3B in cash and equivalents.
- Can Thermo Fisher Scientific cover its short-term obligations?
- Its current ratio is 1.53 — current assets exceed current liabilities.
- Where does Thermo Fisher Scientific's balance sheet data come from?
- Every line is extracted from Thermo Fisher Scientific's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
